Structural Heart Disease

Structural heart diseases include any issues preventing normal cardiovascular function due to damage or alteration to the anatomical components of the heart. This is caused by aging, advanced atherosclerosis, calcification, tissue degeneration, congenital heart defects and heart failure. The most commonly treated areas are the heart valves, in particular the mitral and aortic valves. These can be replaced through open heart surgery or using cath lab-based transcatheter valves or repairs to eliminate regurgitation due to faulty valve leaflets. This includes transcatheter aortic valve replacement (TAVR). Other common procedures include left atrial appendage (LAA) occlusion and closing congenital holes in the heart, such as PFO and ASD. A growing area includes transcatheter mitral repair or replacement and transcatheter tricuspid valve repair and replacement.

An FDA panel will discuss its recommendations related to Abbott's TriClip G4 transcatheter edge-to-edge repair (TEER) system for tricuspid regurgitation.

FDA advisory panel votes in favor of Abbott’s TriClip device for tricuspid regurgitation

After hours of discussion, the panel determined that the benefits of using the TriClip G4 TEER system to treat TR outweigh any potential risks. 

An FDA panel will discuss its recommendations related to Abbott's TriClip G4 transcatheter edge-to-edge repair (TEER) system for tricuspid regurgitation.

FDA panel to consider Abbott’s TriClip device for tricuspid regurgitation

The panel's decision will be based on data from the TRILUMINATE study, which was ultimately positive for Abbott, but did lead to certain questions about patient outcomes.

AI cardiology heart artificial intelligence deep learning

AI could be a game-changer for TAVR, but cardiologists remain ‘irreplaceable’

The rise of TAVR as a go-to treatment option for many AS patients has been one of the biggest stories in cardiology for several years now. How will advanced AI models impact this trend going forward? 

doctor examines patient data on their tablet

TAVR vs. SAVR after 10 years: Similar safety risks, but researchers uncover several key differences

TAVR continues to gain momentum as a go-to treatment option for severe AS, making it more important than ever to investigate long-term outcomes. This latest analysis, published in European Heart Journal, focused on 280 patients randomized to undergo either transcatheter or surgical aortic valve replacement.

FDA approves first transcatheter tricuspid valve replacement device, the EVOQUE system from Edwards Lifesciences

Edwards makes history, receives FDA approval for transcatheter tricuspid valve replacement device

The approval, based on positive results from the TRISCEND II trial, represents a significant milestone for the treatment of severe tricuspid regurgitation. 

Royal Philips X11-4t Mini 3D TEE transducer

FDA clears smaller 3D TEE transducer for imaging children, high-risk adult patients

The newly approved device is much smaller than previous offerings, helping operators capture 3D images during structural heart evaluations. 

heart surgery surgeons

SAVR in the TAVR era: Volumes are down, but it remains the go-to choice for certain patient populations

Annual SAVR volumes in the United States decreased by a whopping 44.5% from 2012 to 2022. However, heart teams across the country seem to agree that surgery is a safer, more effective treatment option than TAVR when patients present with bicuspid aortic valves. 

ACC 2023 ACC.23 American College of Cardiology

American College of Cardiology announces late-breaking research for ACC.24 in Atlanta

The group's annual meeting heads to Atlanta this April. TAVR, GLP-1 agonists, medical imaging guidance and blood pressure control are just some of the topics that will be presented during late-breaking sessions.

Around the web

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.